Research & Development


Mochida Pharmaceutical strives to provide medicines that correspond to patients ongoing requirements as quickly as we can.
We maximize foresight and originality in all processes, based on our unique research and development capabilities and diverse technological know-how cultivated over many years.
In order to make our pharmaceutical research even more efficient, we are enhancing development pipelines by introducing candidate drugs for development at an early stage by promoting “open innovation.”


As of February 8, 2019
Code Name Stage Indications Formulation Remarks
FYU-981 dotinurad Filed Gout and hyperuricemia Oral Co-development with Fujiyakuhin
Filed by Fujiyakuhin
MJR-35 dienogest Filed Dysmenorrhea Oral Licensed-in from Jenapharm (a subsidiary of Bayer AG)
In-house development<Japan>
MD-0901 mesalazine Phase Ⅲ Ulcerative colitis
(pediatric indication)
Oral Licensed-in from Shire Pharmaceuticals Group
In-house development<Japan>
MND-2119 ethyl icosapentate Phase Ⅲ Hyperlipidemia Oral In-house development<Japan>
MLD-55 escitalopram Phase Ⅲ Depression
(pediatric indication)
Oral Licensed-in from Lundbeck
In-house development<Japan>
MD-711 treprostinil Phase Ⅱ / Ⅲ Pulmonary arterial hypertension Inhalant Licensed-in from United Therapeutics
In-house development<Japan>
MND-21 ethyl icosapentate Phase Ⅰ Hypertriglyceridemia Oral Development area :China
Collaboration with Sumitomo Pharmaceuticals (Suzhou)
LBAL adalimumab - Rheumatoid arthritis Injection Biosimilar
Licensed-in from LG Chem
In-house development<Japan>
(Multi-Regional Clinical Trial in Japan and Korea)
RGB-10 teriparatide - Osteoporosis Injection Biosimilar
Licensed-in from Gedeon Richter
In-house development<Japan>
[Medical device]
dMD-001 sodium alginate Therapeutic exploratory study (Pilot study) Articular cartilage lesion   In-house development<Japan>

The development stage of biosimilars is not disclosed.